Provectus Biopharmaceuticals Inc PVCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PVCT is a good fit for your portfolio.
News
-
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers
-
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
-
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
-
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
-
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines
-
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
-
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting
-
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
Trading Information
- Previous Close Price
- $0.19
- Day Range
- $0.19–0.19
- 52-Week Range
- $0.06–0.22
- Bid/Ask
- $0.18 / $0.19
- Market Cap
- $81.72 Mil
- Volume/Avg
- 138,051 / 343,314
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (HXs). Its lead HX molecule is named rose bengal sodium. The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of its current clinical development programs and the preclinical formulations of its current drug discovery programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 4
- Website
- https://www.provectusbio.com
Valuation
|
Metric
|
PVCT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PVCT
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.15 |
Interest Coverage | −13.35 |
Quick Ratio
PVCT
Profitability
|
Metric
|
PVCT
|
|---|---|
Return on Assets (Normalized) | −180.52% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
PVCT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xqdtxtxvrm | Nrvq | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zgdtypcfk | Fwzwbgm | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cmfqtxms | Khdqwqd | $99.6 Bil | |
MRNA
| Moderna Inc | Zntwqwg | Fzj | $38.8 Bil | |
ARGX
| argenx SE ADR | Dcyhlwq | Jbh | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Rdnqjrgjb | Tvfvl | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ygvsqzjk | Jpzwk | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xdbnghrv | Xmczxy | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xdxkyygtg | Hkmvfvr | $12.4 Bil | |
INCY
| Incyte Corp | Cwknjmtmm | Rfnfdg | $11.9 Bil |